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OXPHOS defectMultiple respiratory chain deficiencies represent a common cause of mitochondrial diseases and are associated
with a wide range of clinical symptoms. We report a subject, born to consanguineous parents, with growth
retardation and neurological deterioration. Multiple respiratory chain deficiency was found inmuscle and fibro-
blasts of the subject aswell as abnormal assembly of complexes I and IV. Amicrosatellite genotyping of the family
members detected only one region of homozygosity on chromosome 17q24.2–q25.3 in which we focused our
attention to genes involved in mitochondrial translation. We sequenced MRPL12, encoding the mitochondrial
ribosomal protein L12 and identified a c.542C>T transition in exon 5 changing a highly conserved alanine into
a valine (p.Ala181Val). This mutation resulted in a decreased steady-state level of MRPL12 protein, with altered
integration into the large ribosomal subunit.Moreover, an overall mitochondrial translation defectwas observed
in the subject's fibroblasts with a significant reduction of synthesis of COXI, COXII and COXIII subunits. Modeling
ofMRPL12 showsAla181 positioned in a helix potentially involved in an interface of interaction suggesting that the
p.Ala181Val changemight be predicted to alter interactionswith the elongation factors. These results contrastwith
the eubacterial orthologues of human MRPL12, where L7/L12 proteins do not appear to have a selective effect on
translation. Therefore, analysis of themutated version found in the subject presented here suggests that themam-
malian protein does not function in an entirely analogous manner to the eubacterial L7/L12 equivalent.
© 2013 The Authors. Published by Elsevier B.V. All rights reserved.S, oxidative phosphorylation;
A polymerase
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The mitochondrial machinery responsible for oxidative phosphoryla-
tion (OXPHOS) comprises five enzyme complexes containing approxi-
mately 80 proteins of which only 13 are encoded by the mitochondrial
genome (mtDNA) [1]. OXPHOS deficiencies affecting a single or multiple
complexes can result from mutations in either mitochondrial or nuclear
genes and are associated with a variety of disease mechanisms [2,3].
With the advent of Next Generation Sequencing there is an increasing
number of pathogenic mutations being identified that are not solely re-
stricted to the 80 genes encodingOXPHOS components, thus highlighting
the importance of mechanisms impacting onmitochondrial gene expres-
sion [4,5]. Combined OXPHOS deficiencies can arise from alterations in
mtDNA, its maintenance [6], cardiolipin levels [7,8], or where none of
these are affected, from direct defects in synthesis of mitochondrially
encoded proteins [9]. This last group constitutes a heterogeneous mix of
patients suffering from awide range of clinical symptomsmaking clinical
diagnosis difficult [10]. Genetic diagnosis is yet more elusive in children
with mitochondrial disease where unidentified nuclear mutationsserved.
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compounded by our relatively poor understanding of the complex mo-
lecularmachinery that drives translation inmitochondria. This machin-
ery comprises over a hundred proteins [12], all of which are putative
candidate genes for translation deficiencies in human. Indeed, transla-
tion deficiencies represent a growing cause of multiple OXPHOS defi-
ciencies with several published pathogenic mutations in genes related
to the intra-organellar protein synthesis. Although many mutations as-
sociated with impaired mitochondrial translation currently map to
tRNA genes [13] and a few ribosomal RNA (rRNA) [14], the list of nucle-
ar gene mutations is steadily growing as mutations in genes encoding
mitochondrial translation factors such as GFM1 (OMIM: 606639)
[15,16], TSFM (OMIM: 604723) [17] and TUFM (OMIM: 602389) [18];
mitochondrial aminoacyl-tRNA synthetases (RARS2 (OMIM: 611524)
[19], DARS2 (OMIM: 610956) [20], YARS2 (OMIM: 610957) [21],
SARS2 (OMIM: 612804) [22], HARS2 (OMIM: 600783) [23], AARS2
(OMIM: 612035) [24], MARS2 (OMIM: 609728) [25], EARS2 (OMIM:
612799) [26]), FARS2 (OMIM: 611592) [27]; tRNA-modifying enzymes
(PUS1 (OMIM: 608109) [28], TRMU (OMIM: 610230) [29], MTO1
(OMIM: 614667) [30]); other factors (C12orf65 (OMIM: 613541) [31],
TACO1 (OMIM: 612958) [32], LRPPRC (OMIM: 607544) [33], C12orf62
(OMIM: 614478) [34]) and mitochondrial ribosomal proteins
(MRPS16 (OMIM: 609204) [35], MRPS22 (OMIM: 605810) [36],
MRPL3 (OMIM: 607118) [5]) have been successively reported
(reviewed in Ref. [14]). Relatively few cases of OXPHOS deficiencies as-
sociated with mutations in mitochondrial ribosomal proteins (MRPs)
have been described so far. MRPS16 mutations have been described in
only one family with agenesis of corpus callosum and dysmorphism.
MRPS22mutations lead to cardiomyopathy, hypotonia and tubulopathy
in a first family and Cornelia de Lange-like dysmorphic features, brain
abnormalities and hypertrophic cardiomyopathy in another family. Fi-
nally, we recently identified MRPL3 mutations in four siblings of the
same family presenting cardiomyopathy and psychomotor retardation.
Since the mammalian mitoribosome (55S) is ~2 megadalton machine
consisting of approximately 80 components that make up the 28S
small (SSU) and 39S large subunit (LSU), it is likely thatmore pathogen-
ic mutations in the constituent polypeptides will be uncovered. One of
the substantial differences between the mammalian mitoribosome
and those of eubacteria (70S) or the eukaryotic cytosol (80S) is the re-
versal in the protein to rRNA ratio. The 70S and 80S particles contain
~70% rRNA, whilst human mitoribosomes contain ~70% protein. This
change in the ratio represents both an acquisition of new MRPs as
well as loss of bacterial orthologues [37,38]. MRPL12 does have a bacte-
rial orthologue, which through its interactions with translation factors
is important in protein synthesis regulating both speed and accuracy
[39–41].
Here we investigate the genetic basis of disease in a subject born to
consanguineous parents, who initially presented with growth retarda-
tion and then neurological distress, with evidence of compromised
mitochondrial protein synthesis. We have identified the causative
mutation to be in MRPL12, encoding a protein of the large subunit of
mitochondrial ribosome. This is an important finding indicating that
the function and consequence of dysfunction cannot automatically be
extrapolated from an apparent orthologue. We show that proteins
involved in mitochondrial translation, even close orthologues as sub-
mitted here, can defy predictions. Moreover, mutations in such genes
that should affect all mitochondrially encoded gene products can exert
respiratory chain complex specific defects.
2. Materials and methods
2.1. Analysis of oxidative phosphorylation activities
Spectrophotometric assays of respiratory chain and complex V
enzymes were carried out as previously described [42]. Mitochondrial
suspension from cultured skin fibroblasts was obtained after suspending50 μl of frozen cells in 1 ml of mitochondria extractionmedium (20 mM
Tris–HCl (pH 7.2), 250 mM sucrose, 2 mM EGTA, 40 mM KCl, 1 mg/ml
BSA) supplemented with 0.01% (w/v) digitonin and 10% Percoll (v/v).
After 10 min at 4 °C, the sample was pelleted, washed in extraction
medium and pelleted before resuspension in 30 μl of extractionmedium
for respiratory chain enzyme measurements.2.2. Microsatellite genotyping and mutation screening
A genome-wide search for homozygosity was undertaken with 382
pairs of fluorescent oligonucleotides from the Genescan Linkage
Mapping Set, version II (Perkin-Elmer) under conditions recommended
by the manufacturer. Amplified fragments were electrophoresed and
analyzed with an automatic sequencer (ABI 377). The polymorphic
markers had an average spacing of 10 cM throughout the genome.
Genes encoding mitochondrial proteins were selected in Mitocarta
[43]. The exons and exon–intron boundaries of theMRPL12 gene were
amplified using specific primers (sequences available on request)
with initial denaturation at 96 °C — 5 min, followed by 30 cycles of
96 °C — 30 s, 55 °C — 30 s, 72 °C — 30 s, and a last extension at 72 °C
for 10 min. Amplification products were purified by ExoSapIT
(Amersham, Buckinghamshire, UK) and directly sequenced using the
PRISM Ready Reaction Sequencing Kit (Perkin-Elmer, Oak Brook, IL)
on an automatic sequencer (ABI 3130xl; PE Applied Biosystems, Foster
City, CA).2.3. Cell culture
Human skin fibroblastswere cultured in DMEMmedium (Dulbecco's
modified Eagle'smedium, Gibco) supplementedwith 10% (v/v) fetal calf
serum (FCS), 2 mM L-glutamine, 50 μg/ml uridine, 110 μg/ml pyruvate,
10,000 U/ml penicillin G and 10,000 μg/ml streptomycin.2.4. Protein analysis
For blue native-polyacrylamide gel electrophoresis (BN-PAGE),
mitochondria and OXPHOS complexes were isolated as described
[44]. Solubilized OXPHOS proteins (20 μg) were loaded on a 4–16%
(w/v) polyacrylamide non-denaturing gradient gel (Invitrogen).
SDS–PAGE analysis was performed on either solubilized mitochondrial
proteins (40 μg) or cell lysate (50 μg) extracted from cultured skin
fibroblasts. After electrophoresis, gels were transferred to a PVDFmem-
brane (GE-Healthcare) and processed for immunoblotting.2.5. Metabolic labelling of mitochondrial translation products
In vitro labeling of mitochondrial translation products was a
modification fromChomynet al. [45]. Essentially, cultured skinfibroblasts
were preincubated in methionine/cysteine-free DMEM (2 × 10 min)
followed by a 10 min in the presence of emetine (100 μg/ml).
Radiolabel (125 μCi/ml EasyTag™ express35S protein labelling
mix — NEG772002MC, PerkinElmer) was then added for 1 h at
37 °C and chased for 1 h. Cells were harvested in cold 1 mM EDTA/PBS,
washed 3 times in cold PBS and the pellet resuspended in 30 μl PBS
containing 1× EDTA free protease inhibitors (Roche) and 1 mM PMSF.
Samples were treated with 2× dissociation buffer (20% (v/v) glycerol,
4% (w/v) SDS, 250 mM Tris–HCl pH 6.8, 100 mM DTT) and 12 U
Benzonase nuclease (Novagen) for 1 h and separated on a 15% (w/v)
SDS–PAGE. The gel was fixed overnight (3% (v/v) glycerol, 10% (v/v)
acetic acid, 30% (v/v) methanol) and vacuum dried (60 °C, 2 h).
Radiolabelled proteins were visualized by PhosphorImage and analyzed
with Image-Quant software (Molecular Dynamics, GE Healthcare).
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The three dimensional structure of the humanMRPL12 (residues 64 to
198) wasmodeled by comparative proteinmodeling and energyminimi-
zation, using the Swiss-Model program (http://swissmodel.expasy.org/)
in the automated mode. The 2 Å coordinate set for the ribosomal protein
L12 from Thermotoga maritima (PDB code: 1dd3) was used as a template
for modeling the human MRPL12 protein. Swiss-Pdb Viewer 3.7 (http://
www.expasy.org/spdbv) was used to analyze the structural insight into
MRPL12 mutation and visualize the structures.
2.7. Cell lysates, Westerns and isokinetic sucrose gradients
Cell lysates were prepared from fibroblasts by addition of cold lysis
buffer (50 mM Tris–HCl pH 7.5, 130 mM NaCl, 2 mM MgCl2, 1 mM
PMSF, 1% (v/v) NP-40) to cell pellets, which were vortexed for 30 s,
centrifuged at 600 g for 2 min (4 °C) to remove nuclei and the superna-
tant retained. These were used for standard westerns as described [46].
Mitochondria were prepared as above and lyzed in 50 mMTris–HCl pH
7.4, 150 mMNaCl, 1 mM EDTA, 1% Triton X-100, protease inhibitor mix
(EDTA free, Roche), 1 mM PMSF, 10 mM MgCl2. Mitochondrial lysates
(0.3 mg) were loaded on a isokinetic sucrose gradient (1 ml 10–30%
(v/v)) in 50 mM Tris–HCl (pH 7.2), 10 mM Mg(OAc)2, 40 mM NH4Cl,
0.1 M KCl, 1 mM PMSF, 50 μg/ml chloramphenicol), and centrifuged
for 2 h 15 min at 100,000 g at 4 °C. Fractions (100 μl) were collected
and 10 μl aliquots were analyzed directly by western blotting [47].
Immunodetection was performed using the following primary
antibodies: anti-CI-Grim19, CII-SDHA 70 kDa, CIII-core2, CIV-COXI,
CIV-COXII, CV-subunit β, cyt c, NDUFB8 (mouse monoclonal antibod-
ies, MitoSciences); anti-MRPL3 goat polyclonal, MRPS18B rabbit
polyclonal, MRPS25 rabbit polyclonal and ICT1 rabbit polyclonal anti-
bodies (Protein Tech Group, Inc., Chicago); anti-DAP3 mouse mono-
clonal, POLRMT rabbit polyclonal (Abcam); and anti-Porin, mouse
monoclonal antibodies (Invitrogen). Anti-MRPL12 rabbit polyclonal
antibody was custom made (Eurogentec). Secondary antibody detec-
tion was performed using peroxidase-conjugated anti-rabbit, anti-
goat or anti-mouse IgG (Abcam or Dako). The signal was generated
using ECL+ (Pierce, Rockford, USA) and visualised by phosphorimaging
and analyzed by ImageQuant software.
2.8. RNA and Northern blotting
RNA was isolated from fibroblasts using Trizol following manufac-
turer's protocol (Invitrogen). Northern blots were performed as
described [48]. Briefly, aliquots of RNA (5 μg) were electrophoresed
through 1.2% (w/v) agarose under denaturing conditions and trans-
ferred to GenescreenPlus membrane (NEN duPont) following the
manufacturer's protocol. Radiolabelled probes were generated using
random hexamers on PCR-generated templates corresponding to
internal regions of the relevant genes.
3. Results and discussion
3.1. Clinical report
The subject, a boy, was born to first cousin Roma/Gypsy parents by
cesarean section, at 41 weeks of pregnancy with severe general
hypotrophy (birth weight 2250 g, height 48 cm, Occipitofrontal
Circumference 34 cm). His clinical examination at birth was normal
and initial investigations failed to identify the cause of his severe
hypotrophy (normal blood caryotype, heart ultrasound, bone age,
CT scan and metabolic workup). He failed to thrive thereafter and
was repeatedly admitted in the first 12 months for gradual worsening
of his condition (weight and height: −4SD, OFC: −2SD). Clinical
examination at 10 months showed severe denutrition, muscle weak-
ness but detectable deep tendon reflexes and no major trunkhypotonia. He started walking with aid at 12 months. Basal growth
hormone (GH) levels in plasma were normal (0.5 ng/ml) but plasma
IGF1 was very low (0.07 U/ml, normal 0.2). Stimulation by ornithine
triggered an adequate elevation of plasma GH with correction of plas-
ma IGF1 (GH: 46.9 ng/ml, IGF1: 0.2 U/ml, and 0.45 U/ml following
GH administration). These results ruled out a dwarfism of endocrine
origin. Yet, high plasma lactate (3.5 to 4.4 mmol/l, normal below
2.2) prompted skeletal muscle, liver and skin biopsies that revealed
a multiple respiratory chain enzyme deficiency in muscle and liver
homogenate and cultured skin fibroblasts (Table 1) [42].
He had a first episode of generalized tonic seizure aged 2 years and
his neurological condition rapidly worsened following an episode of
acute fever (40 °C) caused by a respiratory infection. At that age, he
had severe denutrition, flat weight curve, no weight and height gain
(−5 SD) and amildly enlarged liver. Neurological examination revealed
overt psychomotor retardation, severe trunk hypotonia, inability to sit
and stand unaided and no speech. Intermittent horizontal nystagmus,
with cerebellar ataxia and tremor were noted. He had a mild facial
dysmorphism, with round face, epicanthic folds, arched palate, short
neck, low-set ears and a unique bilateral median palmar crease. Brain
MRI showed T1 hyposignal and T2 hypersignal of white matter and
basal ganglia. Rapid aggravation of respiratory conditions required
endotracheal intubation and assisted ventilation. Plasma lactates rose
to 3.3–4.2 mmol/l, he gradually developed abnormal limb movements
then fell into a deep coma, and died following a cardiac arrest.
During the next pregnancy, the mother expected dizygotic twin
fetuses. A prenatal diagnosis based on assessment of respiratory chain
enzyme activities in cultured skin fibroblasts on amniotic fluid was
offered. Hemoglobin contamination of the samples rendered the very
low respiratory chain activities; despite this the activity ratios clearly
showed a severe complex IV deficiency in cells from the fetus twins
leading to termination of the second pregnancy. The same test was
normal in the third pregnancy and a normal baby girl was born, now
14 years old (Table 1).
3.2. Blue native-PAGE analysis
Whilst skin fibroblasts were propagated for enzyme analysis it was
clear that those from the subject harboring themutation had a reduced
doubling time on glucose medium compared to control lines (data
available on request). Cell extracts were subsequently prepared and
SDS–PAGE/western blot analysis revealed reduced steady-state level
of COXII subunit, consistent with the decreased CIV activity (Fig. 1A).
Moreover, we also observed a decreased amount of nuclear encoded
protein NDUFB8 (Fig. 1A), which joins late in complex I assembly [44]
and is consistent with the low CI activity in the biopsies. These
decreases were consistent with the BN-PAGE data from fibroblast
mitoplasts (Fig. 1B, method as described [49]). Both complexes I and
IV, detected by anti-GRIM19 antibody or mitochondrially-encoded
COXI,were severely decreased in the subject, which in contrast exhibited
control levels of complex II (70 kDa SDHA subunit) and complex III (Core
2 subunit) (Fig. 1B). No partial complexes were observed.
3.3. Identifying the causative mutation by Microsatellite genotyping and
mutation screening
In order to identify the causative mutation a genome-wide search
for homozygosity was undertaken using 382 polymorphic microsatel-
lite markers (Genescan Linkage Mapping Set, version II (Perkin-Elmer).
We obtained evidence for homozygosity in all affected individuals at
loci D17S785, D17S784, and D17S928 on chromosome 17q24.2–q25.3
(Fig. 2A). No other homozygous region was found with other markers.
This 32.7 cM region was then refined by additional microsatellite
markers reducing the critical region to the 25 cM interval, defined by
loci D17S1352 and D17S928. This corresponds to a 8.4 Mb physical
region containing more than 170 genes, 10 of which encode
Table 1
Respiratory chain activities in muscle mitochondria, liver homogenate and fibroblasts.
Muscle
mitochondria
Liver
homogenate
Liver homogenate Fibroblasts Amniotic cells
P C P C Twin 1 fetus Twin 2 fetus C P C Twin 1 fetus Twin 2 fetus 3rd pregnancy C
Absolute activities (nmol/min/mg prot)
CI – – – – – – – 17 27–44 – – – –
CII 170 75–157 – – 63 57 74–196 59 33–71 – – – –
CIII 697 494–1004 493 128–217 106 73 70–236 505 318–820 1.44 2.1 16.5 19–21
CIV 374 540–1073 7 131–241 57 32 68–284 90 189–429 0.88 0.77 32 26–36
CV 538 209–454 – – – – – 100 53–133 – – – –
CI + III 89 113–311 27 35–67 – – – – – – – – –
CII + III 443 164–357 365 50–98 37 23 38–104 167 69–146 2.22 1.38 8.7 6.5–8.4
CS – – – – 65 45 40–104 293 112–264 – – – –
Activity ratios
CIV/CI + III 4.2 3.4 ± 0.8 – – – – – – – – – – –
CIV/CII + III 0.8 3.1 ± 0.5 0.01 3.0 ± 0.4 1.5 1.39 2.7 ± 0.3 0.5 3.0 ± 0.2 0.61 0.55 3.6 2.1–3.3
CIV/CI – – – – – – – 5.4 10.1 ± 1.0 – – – –
CIV/CII – – – – – – – 1.5 6.1 ± 0.7 – – – –
CIV/CIII 0.5 1.5 ± 0.2 0.01 2.0 ± 0.6 0.54 0.4 1.2 ± 0.1 0.2 0.6 ± 0.04 0.39 0.37 1.9 0.7–1.2
CIV/CV 0.7 2.5 ± 0.8 – – – – – 0.9 3.5 ± 0.4 – – – –
CI–CV, complexes I–V; CS, citrate synthase; P, subject; C, control. Abnormal activity values and ratios are shown in bold.
Spectrophotometric assays of respiratory chain and complex V enzymes were carried out as previously described [42]. Haemoglobin contamination of amniotic cells reduced
accuracy of the absolute values of RC complex activities but not the ratios.
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targeted (FDXR (MIM 103270), ICT1 (MIM 603000), ATP5H (MIM
607196), MRPS7 (MIM 611974), SLC25A19 (MIM 606521), MRPL38
(MIM 611844), PGS1 (NM_024419),MRPL12 (MIM 602375), SLC25A10PC
CI - Grim19
CV – F1β 
CII - SDHA 
CIII - Core 2
CIV - COXI 
NDUFB8
COXII
Cyt c
Porin
C PA
B
Fig. 1. Steady state levels of the oxidative phosphorylation components and complexes.
A. Western blot analysis was performed on cytoplasmic extracts (40 μg) of cultured
patient (P) and control (C) fibroblasts to determine steady state levels of COXII
(MitoSciences). In the absence of other antibodies to mitochondrially encoded pro-
teins, NDUFB8 (MitoSciences) was monitored as a marker for Complex I. Levels of
cytochrome c (MitoSciences) and porin (Invitrogen) were determined as controls for
the respiratory chain and mitochondrial mass respectively. B. BN-PAGE of mitochon-
dria prepared from cultured skin fibroblasts of patient (P) and control (C) was ana-
lyzed by western using antibodies (all MitoSciences) directed against GRIM19, SDHA
70 kDa, Core 2, COXI and F1β subunit to identify steady state levels of complexes I, II,
III, IV and V respectively.(MIM 606794), FASN (MIM600212)). Considering themultiple RC defi-
ciency observed in patient muscle, liver and fibroblasts and the abnor-
mal BN-PAGE pattern reminiscent of translation deficiencies, we
focused on genes involved in mitochondrial translation, excluding mu-
tations inMRPS7,MRPL38 and ICT1 by direct sequencing.
Sequencing of MRPL12 exons and exon–intron boundaries on
genomic DNA (primer sequences available on request) from the
affected child identified a homozygous c.542C>T transition in exon
5 (RefSeq accession number NM_002949.3, Fig. 2B). This mutation
changed a highly conserved alanine into a valine (p.Ala181Val, Fig. 2C)
and was predicted by Polyphen2 (http://genetics.bwh.harvard.edu/
pph2/) and SIFT (http://sift.jcvi.org/) software to be “probably damag-
ing” and “deleterious” respectively. The parents were heterozygous
for the mutation, both twin fetuses were homozygous and the healthy
girl was wild-type homozygous. This mutation was absent from 100
controls of the same ethnic origin and from all SNP databases. Further,
no additional MRPL12 mutation could be identified in two other
unrelated subjects with similar clinical presentation and biochemical
defect.
To demonstrate the deleterious nature of the p.Ala181Val MRPL12
substitution we used, overexpression of wild-type or mutant human
MRPL12 cDNA in the SV40-immortalized fibroblasts but rather reca-
pitulating the respiratory phenotype of the patient fibroblasts, this
was found to be lethal. Cells stopped growing, became polynucleated
and progressively died.
3.4. In silico analysis of the putative impact of A181V substitution
HumanMRPL12 is 27.5% identical in amino acid sequence to the pre-
viously crystallized T. maritima L12 ribosomal protein. The C-terminal
domain (CTD) (107 to end in Escherichia coli) is conserved in evolution
[50] and is required for initial binding and GTPase activation for both
EF-Tu and EF-G. Indeed, both EF-Tu and EF-G have greatly diminished
GTPase activity on ribosomes lacking the CTD of L12 [51,52]. Superim-
position of MRPL12 with the Thermus thermophilus 70S ribosome (PDB
code: 2WRL) lacking L7/L12 stalk proteins shows that MRPL12 Ala181
is located within this highly conserved region (Fig. 3A). Moreover,
modeling of MRPL12 shows Ala181 positioned in a helix potentially in-
volved in translation factor interactions (Fig. 3A/B). Bacterial L7/L12
CTDs also contain a number of strictly conserved residues that are in-
volved in the initial contact with elongation factors [52,53] and crucial
for translation [54]. Alanine is one of the best helix forming residues
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A181V
Homo sapiens    PVDKVKLIKEIKNYIQGINLVQAKKLVESLP---QEIKANVAKAEAEKIK
Bos taurus    PVDKVKLIKEIKNYVQGINLVQAKKLVESLP---QEIKANVAKAEAEKIK
Mus musculus    PVDKVKLIKEIKNYVQGINLVQAKKLVESLP---QEIKANVAKAEAEKIK
Xenopus laevis   ATDKVKLIKEVKNCIQGLNLVQAKKLVEALP---QEIKANVSKDEAEKIK
Gallus gallus   ATDKVKLIKEVKNFVPGINLVQAKKLVESLP---QEIKANVSKEEAEKIK
Drosophila melanogaster  EKQKVALIKEVKNLLEGMNLVQAKKFVESAP---TIVKEDIPKEEAEKLK
Caenorhabditis elegans  DTKKIAIIKEIRNAIPGLNLVQAKKFVETAP---VNVKEDLGKAEADELK
Arabidopsis thaliana  ASDKIKVIKEVR-TFTSLGLKEAKELVEKVP---AILKQGVTKEEANEII
Saccharomyces cerevisiae  TKTKAKVIKEVK-GLLGLSLVEAKKFVEAAP---KVLKENVAKDDAEKIK
Escherichia coli   A-NKVAVIKAVR-GATGLGLKEAKDLVESAP---AALKEGVSKDDAEALK
Thermotoga maritima  Q-NKIQVIKVVR-EITGLGLKEAKDLVEKAGSPDAVIKSGVSKEEAEEIK
Thermus thermophilus  A-KKLEVIKDVR-AITGLGLKEAKDLAEKGGP----VKEGVSKQEAEEIK
Yersinia pestis   E-NKVAVIKAVR-GATGLGLKEAKDLVESAP---AVLKEGVNKDEAETLK
Pseudomonas aeruginosa  D-KKVNVIKVVR-ELTGLGLKEAKAVVDGAP---GVVKEGASKEEAEAAK
Staphilococcus saprophyticus S-SKIKVVKAVK-EATGLGLKDAKELVDGAP---KVIKEALPKEEAEKLK
        *  ::* ::    .:.* :** ..:        :*    * :*:
nt 542 nt 542nt 542
G G G G G G G GC T AA AT
mother
GA G G G G G G G GCC T AA AA
control
G G G G G G GTC T AA AA
C
patient
Fig. 2. Microsatellite genotyping and mutation screening. A. Pedigree and haplotypes of the family are given (top to bottom) for loci D17S949, D17S1350, D17S1352, D17S1839,
D17S785, D17S784 and D17S928. B. Sequence analysis ofMRPL12 in patient subject (left panel), mother (centre panel) and a control (right panel). The arrow indicates the position
of the mutation. Amplification products were sequenced using the PRISM Ready Reaction Sequencing Kit (Perkin-Elmer, Oak Brook, IL) on an automatic sequencer (ABI 3130xl; PE
Applied Biosystems, Foster City, CA). C. Amino acid alignment of MRPL12 (H. sapiens to S. cerevisiae) and L7/L12 (E. coli to S. saprophyticus) proteins. The arrow indicates the
conserved amino acid that the MRPL12 mutation changes from an alanine to a valine. Below * designates identity, whilst and: indicate increasing levels of similarity.
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perturbing packing interactions or tertiary contacts [55]. Thus, the
p.Ala181Val change might be predicted to alter interactions with
the elongation factors, and since MRPL7/12 bound to elongation fac-
tors is predicted to have a higher affinity for the ribosome [54], the
mutation may in turn affect both rate and accuracy of mitochondrial
translation.3.5. Ribosome assembly
The steady state level of MRPL12 in the subject's fibroblasts was re-
duced to 30% of control value (Fig. 4A and B). The mt-LSU protein ICT1
was also decreased (~30% of control values) as was MRPL3 (by 37%)
suggesting that a consequence of the MRPL12 mutation is a global
defect in assembly of the large ribosomal subunit (mt-LSU). In order
MRPL12
CTD
NTD
Ala181
L10
L11 Ala181
Ala181
A B
CTD
NTD
Fig. 3.MRPL12 and its position in the ribosome. A. The three dimensional structure of the human MRPL12 (residues 64 to 198) was modeled by comparative protein modeling and
energy minimization, using the Swiss-Model program in the automated mode. The 2 Å coordinate set for the ribosomal protein L12 from Thermotoga maritima (PDB code: 1dd3)
was used as a template for modeling the human MRPL12 protein. Swiss-Pdb Viewer 3.7 (http://www.expasy.org/spdbv) was used to analyze the structural insight into MRPL12
mutation and visualize the structures. The A181 residue shown (in red) is localized in a helix that is likely to be at the interface of an interaction with translation factors. B. Potential
MRPL12 interactions within the ribosomal L7/L12 stalk. Swiss-Pdb Viewer 3.7 (http://www.expasy.org/spdbv) was used to superimpose MRPL12 on the Thermus thermophilus 70S
ribosome (PDB code: 2WRL) without L7/L12 stalk proteins. MRPL12, L10 and L11 are shown in green, blue and yellow respectively. The Ala181 residue (in red) is located in the
MRPL12 CTD. The p.Ala181Val change has a high probability of altering interactions of MRPL12 with elongation factors and might be predicted to affect initial binding, decreasing
both rate and accuracy of mitochondrial translation. NTD: N-terminal domain; CTD: C-terminal domain.
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ribosome, we also tested three proteins of the small ribosomal subunit
(SSU), MRPS18B, MRPS25 and DAP3. These were modestly decreased
with levels of ~60–80% of control (Fig. 4A and B). Correspondingly, 16S
and 12S rRNA levels were decreased by 35% and 22% respectively
(Fig. 7A). Since porin indicated that there was no compensatory mito-
chondrial biogenesis and staining of the mitochondrial network with
tetramethylrhodamine methyl ester showed no significant
alteration in amount or distribution of mitochondria (AR and ZCL
unpublished observation) we conclude that the MRPL12 mutation
destabilizes the protein resulting in less mt-LSU and to a lesser
extent of the small subunit.
In order to determine whether the MRPL12 mutation also induced
changes in composition and assembly of the mitochondrial ribosomal
large and small subunits, mitochondrial lysates from cultured fibro-
blasts (subject and control) were fractionated on isokinetic sucrose
gradients (10–30%, as in Ref. [47]). If assembly of either the large
subunit or the entire ribosome was affected then the distribution ofMRPL12
MRPL3
ICT1
DAP3
MRPS18B
MRPS25
Porin
LSU
SSU
PC
1
1
A B
Fig. 4. Analysis of mitoribosomal components. A. Cell lysates (50 μg) from patient (P) and
various components. Polypeptides of the large ribosomal subunit (LSU) included MRPL12
included DAP3 (Abcam), MRPS18B (PTG labs) and MRPS25 (PTG labs). Porin (Invitrogen) w
as described in panel A represent the levels of MRPL12, MRPL3, ICT1, DAP3, MRPS18B andindividual ribosomal proteins would change within the gradient pro-
file. On analysis MRPL12 from the patient was substantially decreased
in all fractions but detectable in the fractions consistent with mt-LSU;
however it was noticeably absent from the free pool (fractions 1 and
2, Fig. 5). This was in contrast to the control that exhibited a pool of
free MRPL12, which has been reported to interact with POLRMT
[56]. MRPL3 was also slightly reduced in subject cells but remained
in fractions consistent with the large subunit. The MRPL12 mutation
impacted more modestly on the small ribosomal subunit, with DAP3
apparently unaffected and MRPS18B found in lower amounts only in
fractions 4 and 5 but otherwise with similar steady state levels and dis-
tribution profile compared to control. Since POLRMT and MRPL12 have
been published as interactors, we analyzed both the steady state level
and gradient distribution of POLRMT to see if these were affected by
the MRPL12 mutation. Overall levels in the subject sample were de-
creased to 63% of control value (Fig. 5B) but distribution in the gradient
appeared largely unaffected with the exception of fraction 11, where
levels were lower than control (Fig. 5A bottom panels).0%
20%
40%
60%
80%
00%
20% C
P
control (C) fibroblasts were separated by SDS–PAGE followed by western to decorate
(Eurogentec), MRPL3 (PTG labs), ICT1 (PTG labs) and small ribosomal subunit (SSU)
as used as a loading control. B. Densitometric values from 3 independent experiments
MRPS25 in subject compared to control fibroblasts.
fractions1 2 3 4 5 6 7 8 9 10 11
28S
39S 55S
10 – 30 % sucrose gradient
1 864 11
DAP3
MRPS18B
mtRNA
polymerase
C
P
mt-SSU
MRPL12
MRPL3
ICT1
mt-LSUC
P
C
P
C
P
C
P
C
P
A
B
Porin
C P
mtRNA
polymerase
Fig. 5. Isokinetic gradient analysis of mitochondrial lysates. A. Mitochondrial lysates were
prepared from patient (P) and control (C) fibroblasts and 300 μg of each was separated
through 10–30% (w/v) isokinetic sucrose gradients. The levels of 28S small subunit
(SSU) and 39S large subunit (LSU) proteins were determined by western blot analysis.
55S corresponds to the assembled mitoribosome. The steady state level (panel B. porin
as loading control) and distribution (panel A) of POLRMT was also examined. Antibodies
as in previous legends except POLRMT (Abcam).
ND5
COXI
ND4
cytb
ND2
ND1
COXIII/COXII
ATP6
ND6
ND3
ND4L
ATP8
C P
Coomassieblue
staining
Autoradiograph
Fig. 6. Mitochondrial protein synthesis. De novo synthesis of mitochondrial proteins
was determined in patient (P) and control (C) fibroblasts under conditions that
inhibited cytosolic translation [45]. In vivo incorporation of 35S-methionine/cysteine
into mitochondrially encoded proteins was visualised by separation of cell lysate
(50 μg) through SDS–PAGE, exposure of the dried gel to a PhosphorImage screen,
followed by Storm and ImageQuant analysis (upper panel). To the right of the gel are
the aligned densitometric profiles of the patient (lower trace) and control (upper
trace). The gel was subsequently rehydrated and stained with Coomassie blue to con-
firm equal loading (lower panel).
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To identify any effect on global mitochondrial protein synthesis, we
studied de novo mitochondrial translation in cultured skin fibroblasts,
as described in Ref. [45]. Although there was an overall decrease inmito-
chondrial translation compared to control, densitometric profiles showed
that certain polypeptides weremore affected than others (Fig. 6). In par-
ticular, there was a significant reduction of synthesis of COXI, COXII and
COXIII subunits. Consistent with the respiratory chain activities, complex
I polypeptides were affected to a lesser extent and cytochrome b from
complex III appears to be spared. Despite the potential role of MRPL12
in translational accuracy, no aberrant translation product could be
detected.
3.7. Steady-state level of mitochondrial transcripts
MRPL12 has been shown to interact with the mitochondrial RNA
polymerase (POLRMT) and to stimulate mitochondrial transcription
[56,57]. Since the steady-state level of POLRMT in subject fibroblasts
was modestly decreased, we analyzed the steady-state level of mito-
chondrial transcripts to see if these were similarly affected. Northern
blots on control and subject fibroblast RNA did not show a decreasethat paralleled the reduced levels of POLRMT. In fact there was a
slight increase of MTND1 in subject cells compared to control, whilst
MTCOI and MTCYB transcripts appeared unaffected (Fig. 7A). Con-
versely, as mentioned earlier, the levels of 16S and 12S rRNA were
modestly decreased (Fig. 7A) in a proportion that was consistent
with the loss of MRPs with which they would associate. Analysis of
the distribution on 10–30% (w/v) sucrose gradients (as in Ref. [58])
of two mt-mRNAs, MTCOI and MTND1, showed a relatively similar
pattern for subject and control but in each case a smaller proportion
of the subject transcript sedimented to the final fraction (data avail-
able on request). This was also true for the 16S and 12S rRNA. As no
major redistribution in the sucrose gradient was observed, it is un-
likely that the MRPL12 mutation causes a global defect in assembly
of the mitoribosome.
Since the levels of POLRMT were slightly decreased with normal
or slightly elevated levels of mt-mRNA, we assessed the stability of
transcripts to see if the half-lives were extended to compensate for
reduced synthesis in order to maintain normal steady state levels.
Mitochondrial transcription was poisoned by addition of low levels
of ethidium bromide and RNA prepared at numerous time points
thereafter (0–16 h). Densitometry of the subsequent Northern dem-
onstrated that half-lives ofMTCOI andMTND1were extended, the lat-
ter more so, consistent with the modest increase in steady state levels
(data available on request).
3.8. MRPL12 dimerization and interaction with the mitoribosome
MRPL12 is the orthologue of eubacterial L7/L12, where L7 is identical
to L12 except that it is N-terminal acetylated. L7/L12 is also phosphory-
lated, which can affect both conformation and binding to partner
MTCO1
MTND1
MTCyb
18S
12S rRNA
16S rRNA
2 µg 5 µg 10 µg
A B
MRPL12
Actin
DAP3
MRPL3
ICT1
C P C P C P C P
S18B
MRPL12
IP 
via 
MRPL12
Input
Mito lysate
15 µg 
Fig. 7. Analysis of mitochondrial transcripts and of MRPs immunoprecipitating with MRPL12. A. Steady-state levels of mitochondrial transcripts from patient (P) and control
(C) fibroblasts were analyzed by Northern blot. Signals were normalized against 18S cytosolic rRNA. Three different amounts (2, 5 and 10 μg) of total RNAs were loaded.
B. MRPL12 was immunoprecipitated from mitochondrial lysates (835 μg) prepared from patient (P) and control (C) fibroblasts. Recovered MRPL12 and co-immunoprecipitating
MRPs were analyzed by western blot (antibodies as previously described).
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been confirmed to be present inmammalianMRPL12 [59]. In eubacteria,
association of L7/12 to the large subunit takes place via the L10 protein
such that two L7/L12 heterodimers normally associate per LSU [60]. In-
terestingly these dimers are actively exchanged on the 70S molecule
without disruption of the ribosomal particle [54,61]. The dimerization
status and number of dimers attached to the human 55S has not been
clarified. In order to identify if the stoichiometry of MRPL12 per
mt-LSUwas altered as a consequenceof themutation,we performed im-
munoprecipitation (IP) analysis on subject and control fibroblasts using
antibodies toMRPL12. Analysis of the immunoprecipitate demonstrated
similar levels small subunit polypeptides including DAP3 and MRPS18B
in subject and control samples. In contrast, the total amount of MRPL12
was reduced (Fig. 7B). In the patient the IP is restricted toMRPL12 in the
large subunit or the fully assembled 55S with the total amount of
MRPL12 being reduced as it lacks the “free” population. The densitomet-
ric measurements indicate that the patient IP has ~49% MRPL12 com-
pared to control, in accordance with the gradient and steady state data.
ICT1 appears to be sensitive to the MRPL12 levels and so is reduced in
both the IP (~58% of control) and in the steady state westerns (Fig. 4).
The lower levels of MRPL12 could reflect loss of multimerization but
since the region in the bacterial protein involved in multimerization is
towards the N-terminus [62], thismutation is unlikely to have an impact
on dimer/multimer formation. The translation factor bound dimer has
been suggested to have an increased affinity for the ribosome [54,61].
Thus a possible explanation is that themutation affects translation factor
binding, thereby reducing the affinity of the mutant MRPL12 for the ri-
bosome. If this were the case, however, then we would expect an in-
crease in the pool of free MRPL12 whereas the subject exhibits a
reduced pool of freeMRPL12,which interactswith POLRMT [57]. The im-
munoprecipitation was performed using an MRPL12 specific antibody
and so should contain all free MRPL12, MRPL12 associated with
uncomplexed mt-LSU and MRPL12 as part of the fully assembled 55S.
Since the levels of small and large subunit proteins appeared to be similar
in subject and control, these data suggest that the mt-LSU and 55S as-
sembly are unaffected by the mutation consistent with the gradient
data for the protein and RNA components. Thus the reduced levels of
mutant MRPL12 in this subject correspond to i) loss of stability, ii) a de-
crease in the free pool that is believed to interact with the mitochon-
drial RNA polymerase and iii) reduced translation potentially
resulting from decreased interactions with translation factors, but
with no detectable increase in aberrant translation products.
In conclusion,we report amutation in humanMRPL12 that results in
growth retardation and neurological distress. It is interesting to notethat whereas the eubacterial orthologue is not essential for in vitro
translation assays, thisMRPL12mutation induces amitochondrial trans-
lation defect in human. This lack of predictability between orthologous
proteins makes it important to examine and not assume what impact
mutant forms or loss of MRPs may have on mitochondrial homeostasis
and the resulting clinical manifestation. The data presented here pro-
vide another example, amongst a growing list of translation factors,
which despite their apparent universal contribution to the synthesis
of all mitochondrially encoded proteins, has a selective effect on the
different oxidative phosphorylation complexes.Acknowledgments
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